Phase 2
Completed N=15
Pazopanib In Stage IIIB/IV NSCLC Lung Cancer After Progression on First Line Therapy Containing Bevacizumab
Source: ClinicalTrials.gov NCT01262820 ↗Enrolled (actual)
15
Serious AEs
33.3%
Results posted
Sep 2016
Primary outcomePrimary: Disease Control Rate — 13 % of participants with disease control
Summary
This is an open label Phase II Trial that using the investigational anti-cancer agent, Pazopanib to see whether non-squamous non-small cell lung cancer will respond to its use by decreasing the size of the tumor or stopping its growth.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Disease Control Rate |
13 | — |
| SECONDARY Combined Response Rate (CR + PR) of Pazopanib According to RECIST v1.1 |
— | — |
| SECONDARY Progression Free Survival |
10.9 | — |
| SECONDARY Overall Survival |
24.1 | — |
Eligibility Criteria
Inclusion Criteria
- Age 18 or older
- Stage IIIB (with malignant pleural or pericardial effusion or supraclavicular lymph node involvement) or stage IV NSCLC
- Evidence of progression while on bevacizumab
- Patients treated for CNS metastases who are asymptomatic with no requirement for steroids for 2 weeks prior to first dose of study drug
Exclusion Criteria
- Prior malignancy
- Clinically significant gastrointestinal abnormalities
- Presence of uncontrolled infection or nonhealing wound, fracture, or ulcer
- History of cardiovascular conditions within the past 6 months
Data sourced from ClinicalTrials.gov (NCT01262820). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.